Still Seeking to Move Beyond HIV, HCV
Gilead Boosts Cancer Pipeline in $510M YM BioSciences Deal
By Marie Powers
Thursday, December 13, 2012
One day after disclosing a 2-for-1 stock split, Gilead Sciences Inc. surprised the biotech world with a deal to acquire Canadian firm YM BioSciences Inc. in a transaction Gilead valued at $510 million.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.